Methods of diagnosing cervical cancer

Details Methods of diagnosing cervical cancer Methods of diagnosing cervical cancer

2011-07-05

2011-07-05

Salimi, Ali R. (Department: 1648)

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

C435S007100

Reexamination Certificate

active

07972774

ABSTRACT:
The invention provides reagents and methods for detecting pathogen infections in human samples. This detection utilizes specific proteins to detect the presence of pathogen proteins or abnormal expression of human proteins resulting from pathogen infections. Specific methods, compositions and kits are disclosed herein for the detection of oncogenic Human papillomavirus E6 proteins in clinical samples.

REFERENCES:
patent: 4777239 (1988-10-01), Schoolnik
patent: 5204061 (1993-04-01), Covington et al.
patent: 5415995 (1995-05-01), Schoolnik
patent: 5571680 (1996-11-01), Chen
patent: 5610077 (1997-03-01), Davis et al.
patent: 5643752 (1997-07-01), Hawkins et al.
patent: 5648459 (1997-07-01), Cole
patent: 5665535 (1997-09-01), Orth
patent: 5747274 (1998-05-01), Jackowski et al.
patent: 5753233 (1998-05-01), Bleul
patent: 5876723 (1999-03-01), Cole
patent: 6322794 (2001-11-01), Bleul
patent: 6344314 (2002-02-01), Cole
patent: 6391539 (2002-05-01), Orth
patent: 6440696 (2002-08-01), Band et al.
patent: 7312041 (2007-12-01), Lu et al.
patent: 7399467 (2008-07-01), Lu et al.
patent: 2005/0112552 (2005-05-01), Herrero et al.
patent: 2005/0255460 (2005-11-01), Lu et al.
patent: 2007/0128699 (2007-06-01), Lu et al.
patent: 0523391 (1993-01-01), None
GenPept AAH15560, “DLG1 protein [Homo sapiens].,” Jan. 2005.
Gardiol, et al. Mutational Analysis of The Discs Large Tumour Suppressor Identifies Domains Responsible For Human Papillomavirus Type 18 E6-Mediated Degradation. Journal of General Virology, 2002; 83: 283-289.
Gardiol, et al. Oncogenic Human Papillomavirus E6 Proteins Target the Discs Large Tumour Suppressor Fro Proteasome-Medicated Degradation. Oncogene. 1999; 18:5487-96.
Glaunsinger, et al. Interactions of the Pdz-Protein Magi-1 With Adenovirus E4-Orf1 and High-Risk Papillomavirus E6 Oncoproteins. Oncogene. 2000; 19:5270-80.
Guiot, et al. Immunological Detection of E6 Region Protein From Human Papillomavirus Types 16 and 18 In Premalignant Cervical Lesions. Cancer Cells. 1989; 7: 193-196.
Kehmeier, et al. Cellular steady-state levels of “high risk” but not “low risk” human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities. Virology. 2002; 299(1):72-87.
Kiyono, et al. Binding of High-Risk Human Papillomavirus E6 Oncoproteins To The Human Homologue Of TheDrosophilaDiscs Large Tumor Suppressor Protein. Proc. Natl. Acad. Sci. 1977; 94:11612-6.
Lee, et al. Binding of Human Virus Oncoproteins to Hdlg/Sap97, A Mammalian Homolog of theDrosophilaDiscs Large Tumor Suppressor Protein. Proc. Natl. Acad. Sci. 1997; 94:6670-5.
Mathur, et al. Human Papillomavirus (Hpv)-E6/E7 and Epidermal Growth Facter Receptor (Egf-R) Protein Levels In Cervical Cancer and Cervical Intraepithelial Neoplasia (CIN). American Journal of Re. Immun. 2001; 46(4):280-287.
Meschede, et al. Antibodies Against Early Proteins of Human Papillomaviruses As Diagnostic Markers For Invasive Cervical Cancer. J. Clin. Microbiol. 1998; 36:475-80.
Munger, et al. The Role of the Human Papillomaviruses In Human Cancers. Front. Biosci. 2002; 7:d641-9.
NCBI Printout. GenPept AAB91995, putative membrane-associated guanylate kinase 1 (Mus musculus) (Dec. 1997).
Park, et al. HPV-16-related proteins as the serologic markers in cervical neoplasia. Gynecol Oncol. 1998; 69(1):47-55.
Pim, et al. Hpv-18 E6*I Protein Modulates The E6-Directed Degradation of P53 By Binding To Full-Length Hpv-18 E6. Oncogene. 1999; 18:7403-8.
Rosales, et al. Antibodies against human papillomavirus (HPV) type 16 and 18 E2, E6 and E7 proteins in sera: Correlation with presence of papillomavirus DNA. J. Medical Virology. 2001; 65:736-744.
Thomas, et al. HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene. 2001; 20(39):5431-9.
Lee, et al. Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol. Oct. 2000;74(20):9680-93.
Nakagawa, et al. Human scribble (Vartul) is targeted for ubiquitin-mediated degradation by the high-risk papillomavirus E6 proteins and the E6AP ubiquitin-protein ligase. Mol Cell Biol. Nov. 2000;20(21):8244-53.
Thomas, et al. Oncogenic human papillomavirus E6 proteins target the MAGI-2 and MAGI-3 proteins for degradation. Oncogene. Aug. 1, 2002;21(33):5088-96.
European search report dated Jan. 17, 2006 for Application No. 3752248.9.
European search report dated Jan. 19, 2009 for Application No. 8018445.0.
International search report dated May 4, 2004 for PCT Application No. PCTUS03/28508.
Office action dated Feb. 16, 2005 for U.S. Appl. No. 10/630,590.
Office action dated Aug. 10, 2005 for U.S. Appl. No. 10/630,590.
Office Action dated Jul. 6, 2006 for U.S. Appl. No. 11/053,076.
Office action dated Apr. 6, 2007 for U.S. Appl. No. 10/630,590.
Office action dated Aug. 24, 2007 for U.S. Appl. No. 11/650,455.
Office action dated Apr. 8, 2008 for U.S. Appl. No. 11/650,455.
Office action dated Nov. 20, 2008 for U.S. Appl. No. 11/650,455.
Office action dated Jan. 26, 2010 for U.S. Appl. No. 11/650,455.
Office action dated Jul. 20, 2010 for U.S. Appl. No. 11/650,455.

Affiliated with

Also associated with

Rating

Methods of diagnosing cervical cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of diagnosing cervical cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing cervical cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2732036